Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
EBIATLong-Term Debt IssuancesReceivables - Net
Ratios

Regen BioPharma (RGBP) Loans and Notes Receivables (2016 - 2022)

Regen BioPharma (RGBP) has disclosed Loans and Notes Receivables for 5 consecutive years, with $5396.0 as the latest value for Q2 2022.

  • On a quarterly basis, Loans and Notes Receivables changed 0.0% to $5396.0 in Q2 2022 year-over-year; TTM through Jun 2022 was $5396.0, a 0.0% change, with the full-year FY2021 number at $5396.0, changed N/A from a year prior.
  • Loans and Notes Receivables was $5396.0 for Q2 2022 at Regen BioPharma, roughly flat from $5396.0 in the prior quarter.
  • In the past five years, Loans and Notes Receivables ranged from a high of $5396.0 in Q2 2021 to a low of $4551.0 in Q1 2018.
  • A 3-year average of $5079.1 and a median of $5396.0 in 2021 define the central range for Loans and Notes Receivables.
  • Biggest YoY gain for Loans and Notes Receivables was 0.0% in 2018; the steepest drop was 0.0% in 2018.
  • Regen BioPharma's Loans and Notes Receivables stood at $4551.0 in 2018, then grew by 18.57% to $5396.0 in 2021, then changed by 0.0% to $5396.0 in 2022.
  • Per Business Quant, the three most recent readings for RGBP's Loans and Notes Receivables are $5396.0 (Q2 2022), $5396.0 (Q1 2022), and $5396.0 (Q4 2021).